Twist Bioscience Corporation (TWST) Stock Price & Analysis
Twist Bioscience Corporation (TWST) closed at USD 135.47 on Thursday, October 22, 2026, down 9.16% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 135.47; the Oct 22, 2026 session ranged USD 131.85–150.14 on volume of 2,689,748 shares. Market capitalization is —, with a 52-week range of USD 23.3–219.71 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TWST.md
Key facts (TWST)
- Last four reported quarters (through Jun 30, 2026): revenue $432M, net income -$137M (-31.7% margin), free cash flow -$93.1M (SEC filings).
- 1 of 80 tracked superinvestors hold TWST (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Total return with dividends: 1Y +325.6% vs S&P 500 +14.9%; 5Y +15.4% vs S&P 500 +80.3%.
- Next earnings: 2026-11-16, EPS estimate USD -0.2, revenue estimate $124M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TWST)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $132M | $204M | $245M | $313M | $377M | $432M |
| Gross profit | $51.7M | $84.2M | $89.7M | $133M | $191M | — |
| Operating income | -$153M | -$235M | -$217M | -$221M | -$136M | -$145M |
| Net income | -$152M | -$218M | -$205M | -$209M | -$77.7M | -$137M |
| EPS (diluted) | -$3.15 | -$4.04 | -$3.60 | -$3.60 | -$1.30 | — |
| Free cash flow | -$139M | -$226M | -$170M | -$69.2M | -$75.6M | -$93.1M |
| Gross margin | 39.1% | 41.4% | 36.6% | 42.6% | 50.7% | — |
| Operating margin | -115.4% | -115.3% | -88.6% | -70.6% | -36.2% | -33.6% |
| Net margin | -114.9% | -107.0% | -83.5% | -66.7% | -20.6% | -31.7% |
| Revenue growth | +46.9% | +53.8% | +20.4% | +27.7% | +20.3% | — |
| Cash + short-term investments | $478M | $505M | $336M | $276M | $232M | — |
Fiscal years end Sep. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TWST)
Superinvestors (SEC 13F-HR, Q2 2026) (TWST)
1 of 80 tracked investors hold TWST. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.05% | $5.7M | Added +130.1% |
Analysts (TWST)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $115 → $190 |
| 2026-10-12 | Canaccord Genuity | Target raised | Buy | $120 → $205 |
| 2026-10-08 | Jefferies | Initiated | Hold | $150 |
| 2026-10-07 | Barclays | Target raised | Overweight | $112 → $215 |
| 2026-10-01 | Guggenheim | Target raised | Buy | $107 → $212 |
| 2026-09-29 | Leerink Partners | Target raised | Outperform | $160 → $190 |
| 2026-09-18 | BWS Financial | Maintained | Sell | $45 |
| 2026-09-17 | Leerink Partners | Target raised | Outperform | $120 → $160 |
| 2026-09-09 | BWS Financial | Initiated | Sell | $45 |
| 2026-09-09 | UBS | Initiated | Neutral | $144 |
| 2026-08-05 | Piper Sandler | Target raised | Overweight | $85 → $115 |
| 2026-08-04 | Baird | Target raised | Outperform | $113 → $115 |
Total return (dividends reinvested) (TWST)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +325.6% | +15.4% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +327.7% | +2.9% |
| Volatility (annualized) | 77.5% | 79.1% |
| Max drawdown | -35.2% (Oct 2026→Oct 2026) | -91.2% (Nov 2021→May 2023) |
TWST revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| NGS applications | $61.8M | 52.2% | +11.8% |
| DNA synthesis and protein solutions | $56.6M | 47.8% | +38.7% |
| Total revenue | $118.4M | 100% | — |
TWST revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Americas | $77.3M | 65.3% | +30.1% |
| EMEA | $33.6M | 28.4% | +9.4% |
| APAC | $7.5M | 6.3% | +26.4% |
| Total revenue | $118.4M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
TWST suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | At Twist Bioscience | “At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better.” |
| Partner | Boehringer Ingelheim | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
| Partner | TAKEDA PHARMACEUTICAL CO LTD (TAK) | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
| Partner | Ono Pharmaceutical | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
| Partner | Invetx | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
| Partner | Astellas Pharma | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
| Partner | Neogene Therapeutics | “Some of our partners include Bayer, Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Limited, Adicet Bio, Ono Pharmaceutical Ltd., Kyowa Kirin, Invetx, Inc., Astellas Pharma Inc. and Neogene Therapeutics, Inc.” |
Quoted from the company's 10-K filed Nov 17, 2025.
Companies that name TWST in their SEC reports
| Relationship to TWST | Company | Filing | Sentence |
|---|---|---|---|
| partner | Adicet Bio, Inc. (ACET) | 10-K Mar 12, 2026 | “We have entered into multiple strategic agreements and collaborations, including our License and Collaboration Agreement with Regeneron, our Antibody Discovery Agreement with Twist Bioscience Corporation, our License and Collaboration Agreement with CRISPR Therapeutics AG, and our Non-Exclusive License Agreement with the City of Hope.” |
TWST customer concentration
In the period ended Sep 30, 2025, a single direct customer accounted for 10% of revenue, per the company's 10-K filed Nov 17, 2025. The company does not name it.
TWST company outlook (results filed Aug 3, 2026)
- “The following statements are based on Twist's current expectations for fiscal 2026.”
- “For the full fiscal year 2026, Twist expects : • Total revenue in the range of $456 million to $457 million, growth of approximately 21% year over year, compared to prior guidance of $442 to $447 million. • Gross margin to be above 52%.”
- “For the fourth quarter, Twist expects: • Total revenue of approximately $123 million to $124 million, growth of approximately 25% yea r over year at the midpoint, with sequential growth in both DSPS and NGS Applications. • To achieve adjusted EBITDA breakeven.”
Quoted word-for-word from the SEC 8-K results press release.
TWST analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.20 | $-0.19 | +7.4% | $123.6M | 4 |
| Next quarter (ends Dec 2026) | $-0.14 | $-0.10 | +45.3% | $126.4M | 3 |
| Current fiscal year (ends Sep 2026) | $-1.20 | $-1.19 | +0.8% | $456.3M | 5 |
| Next fiscal year (ends Sep 2027) | $-0.40 | $-1.00 | -60.2% | $548.6M | 4 |
TWST options: expected move
Options price a move of about ±24.2% (±$32.45) by Nov 20, 2026, which includes earnings on Nov 16, 2026. Over the last 8 reports the stock moved ±11.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 107.1% | ±24.2% |
| Dec 18, 2026 | 56 | 95.8% | ±30.3% |
| Jan 15, 2027 | 84 | 89.8% | ±34.6% |
| Apr 16, 2027 | 175 | 89.6% | ±49.0% |
| Jun 17, 2027 | 237 | 89.7% | ±56.6% |
30-day implied volatility 106.2% vs 104.9% realized over the last 30 trading days. Put/call ratio (volume) 10.12. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:21 UTC)
| Price | USD 135.47 |
|---|---|
| Change | ▼ 9.16% (down) |
| Previous Close | USD 135.47 |
| Open | USD 135.47 |
| Day Range | USD 131.85 – 150.14 |
| 52-Week Range | USD 23.3 – 219.71 |
| Volume | 2,689,748 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (TWST)
Nexqual's technical model rates TWST "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.46 (neutral) |
| vs SMA50 | Below (USD 149.47) |
| MACD | -3.87 (negative) |
Earnings (TWST)
| Next Earnings Date | 2026-11-16 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $123.58M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.56 vs est -0.28 ▼ miss |
| 2026-03-31 | USD -0.6 vs est -0.53 ▼ miss |
| 2025-12-31 | USD -0.5 vs est -0.52 ▲ beat |
| 2025-09-30 | USD -0.45 vs est -0.5 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financials & Fundamentals (TWST)
| Total Revenue | $431.80M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.20% |
| Gross Margin | +51.96% |
| Operating Margin | -30.65% |
| Profit Margin | -31.66% |
| ROE | -29.59% |
| Debt / Equity | 0.24 |
| Current Ratio | 2.67 |
| Total Cash | $166.84M |
| Total Debt | $108.59M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$93.12M (-21.6% of revenue) |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
Financial Health Score (TWST)
Nexqual rates Twist Bioscience Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:21 UTC.
| Growth | Strong — Revenue +20% YoY (annual) |
|---|---|
| Profitability | Mixed — Gross margin 52%, operating -31% (last 12 months) |
| Balance Sheet | Strong — $167M cash vs $109M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$93M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -30%, ROA -13.1% |
Ownership (TWST)
| Insider Ownership | +0.91% |
|---|---|
| Institutional Ownership | +117.27% |
| Shares Outstanding | 66.30M |
| Float | 61.89M |
| Short % of Float | +20.10% |
Source: Nexqual, October 23, 2026 at 09:21 UTC.
From Twist Bioscience Corporation's Latest SEC 10-K Filing (filed 2025-11-17)
Key Strengths & Strategy (as disclosed to the SEC)
- In fiscal year 2025, we served more than 3,800 customers and reported $376.6 million in revenue, including $215.1 million in revenue from the healthcare sector, $93.2 million in revenue from the chemicals/materials sector, $65.9 million in revenue from the academic research sector and $2.4 million in revenue from the food/agriculture sector.
- The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip.
- We provide end-to-end services, whereby customers can choose to design and/or purchase libraries, or select various discovery platforms for Twist to characterize antibody candidates that bind to the customer's target(s) of interest.
- Our objective is to be the leading provider of synthetic DNA and related solution worldwide, including RNA and proteins, and to leverage our platform to build a leadership position in other life sciences markets in which we have a competitive advantage.
Partnerships
- In October 2024, we entered into an agreement with XOMA Royalty under which they paid Twist $15 million cash in exchange for 50% of future milestone and royalty payments from our existing collaborations as of the date of signing.
- Research and development activities are conducted in collaboration with manufacturing activities to help expedite new products from the development phase to manufacturing and to more quickly implement new process technologies.
Legal & Regulatory Risks (Item 1A, quoted)
- We use biological and hazardous materials that require considerable expertise and expense for handling, storage and disposal and may result in claims against us.
- Our products could in the future be subject to additional regulation by the FDA or other domestic and international regulatory agencies, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
- The enactment of legislation implementing changes in taxation of international business activities, the adoption of other corporate tax reform policies, or changes in tax legislation or policies could impact our future financial position and results of operations.
- We may be involved in lawsuits to protect or enforce our patents and proprietary rights, to determine the scope, coverage and validity of others' proprietary rights, or to defend against third party claims of intellectual property infringement that could require us to spend significant time and money and could prevent us from selling our products or impact our stock price.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | USD 62.85 | ▼ 0.6% |
| KRYS | Krystal Biotech, Inc. | USD 320.13 | ▼ 0.63% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.85 | ▼ 1.58% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 453.34 | ▼ 1.01% |
| IBRX | ImmunityBio, Inc. | USD 8.31 | ▼ 3.82% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 56.63 | ▲ 2.57% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt